Ugandan pharmaceutical company Dei BioPharma has filed a patent application in the United States for a new Ebola vaccine platform designed to protect against multiple strains of the deadly virus, a development the company says could strengthen Africa’s ability to respond faster and more independently when outbreaks hit. The filing, submitted to the U.S. Patent and Trademark Office, covers a …
Read More »
Dr. Mathias Magoola – New mRNA innovation targets major outbreak-causing ebolaviruses, including Zaire, Sudan, Bundibugyo and the West African/Makona lineage KAMPALA, Uganda — Dei BioPharma has announced the submission of a utility patent application to the United States Patent and Trademark Office for a next-generation mRNA vaccine platform designed to provide broad protection against the world’s most dangerous Ebola-causing viruses. × …
Read More »
Kampala — The latest Auditor General’s report on the National Agricultural Research Organisation (NARO) reads like a catalogue of missed opportunities, stalled projects and internal power struggles at Uganda’s top agricultural research body. At the centre of the storm is the Director General, Dr. Yona Baguma, whose four-year contract runs out next year April. Appointed in April 2023 by the …
Read More »
Kampala/Matugga – Troubling signs are emerging from Uganda’s flagship pharmaceutical and biotechnology giant, Dei Biopharma, as reports confirm a massive exodus of top scientists and senior managers from the company’s state-of-the-art vaccine and drug manufacturing complex in Kigogwa–Matugga. The Dei Biopharma manufacturing facility in Matugga, near Kampala, Once hailed as a landmark investment that would anchor Africa’s healthcare self-sufficiency, the …
Read More »
pressug.com News 24 7